Related Experiment Videos
Immunity and vaccine development in Pasteurella multocida infections
B Adler1, R Chancellor, P Homchampa
1Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Journal of Biotechnology
|January 26, 1996
Summary
Lipopolysaccharide (LPS) plays a partial role in immunity against Pasteurella multocida. Attenuated live mutants and iron-regulated outer membrane proteins offer partial protection, highlighting complex immunity strategies.
Area of Science:
- Veterinary immunology
- Bacteriology
- Molecular biology
Background:
- Pasteurella multocida causes significant disease in animals.
- Understanding immunity to P. multocida is crucial for developing effective vaccines.
- Lipopolysaccharide (LPS) and outer membrane proteins are key antigens.
Purpose of the Study:
- To investigate the role of LPS in P. multocida immunity.
- To evaluate the immunogenicity and protective efficacy of attenuated aroA mutants.
- To assess the protective potential of iron-regulated outer membrane proteins.
Main Methods:
- Monoclonal antibody production and passive protection assays.
- Gene cloning, inactivation (aroA gene), and allelic exchange for mutant generation.
- Active immunization with purified LPS, live mutants, and outer membrane fractions.
Main Results:
- Monoclonal antibodies against LPS showed opsonization but not bactericidal activity, conferring partial protection.
- Purified LPS also provided only partial protection in active immunization.
- Live aroA mutants were highly attenuated and conferred homologous protection but not heterologous protection.
- Outer membrane fractions from iron-restricted P. multocida induced partial homologous and heterologous protection.
Conclusions:
- LPS contributes partially to immunity against P. multocida.
- Attenuated live mutants are promising vaccine candidates for homologous protection.
- Iron-regulated outer membrane proteins show potential for broader protection against P. multocida serotypes.